Introduction {#sec1-1}
============

Alpha-lipoic acid has gained considerable interest as an antioxidant. It is readily absorbed from the diet, transported to tissues, and taken up by cells, where a large proportion of it is rapidly converted to its reduced form, dihydrolipoic acid ([@ref1]). It cooperates with rhodanese in the sulfane sulfur metabolism and hydrogen sulfide (H~2~S) release. Sulfane sulfur is an essential storage form of H~2~S in the body ([@ref2], [@ref3]). Therefore, some of the effects observed after alpha-lipoic acid administration can be associated with the action of H~2~S.

In the cardiovascular system, endogenous H~2~S has important physiological effects including vascular tone regulation ([@ref4]). H~2~S induces hypotension *in vivo* ([@ref5]) and vasodilatation *in vitro* ([@ref6]) by opening K~ATP~ channels in vascular smooth muscle cells ([@ref5]-[@ref7]). H~2~S is endogenously produced by the heart tissue as a physiological regulator of cardiac function ([@ref8]). Glibenclamide, a K~ATP~ channel antagonist, attenuates the hypotensive effect of H~2~S *in vivo* and vasodilatation *in vitro* ([@ref3], [@ref7]).

The effect of alpha-lipoic acid on blood pressure was investigated many times in chronic studies ([@ref8]-[@ref12]), but there are no studies on the effect of this compound after a single administration. Alpha-lipoic acid is a drug used in diabetic neuropathy and diabetes, which occurs frequently together with hypertension, especially in obese patients, to treat hypertension. Therefore, knowledge of the potential antihypertensive effect of alpha-lipoic acid even after a single dose and possibly too much pressure reduction is interesting and useful.

Methods {#sec1-2}
=======

The mechanism of the hypotensive effect of alpha-lipoic acid was examined in normotensive rats *in vivo* after a single intraperitoneal administration.

The experiments were conducted on male Wistar rats (weight, 180--250 g). The animals were housed in plastic cages in a room at a constant temperature of 20±2°C with a natural light--dark cycle. They had free access to a standard pellet diet and water. Groups consisted of the following number of animals: group 1, n=7; group 2, n=7; group 3, n=6; group 4, n=8.

The rats in the groups were treated as follows:

Group 1: alpha-lipoic acid at a dosage of 50 mg/kg b.w., i.p., suspended in 1% Tween 80.

Group 2: glibenclamide at a dosage of 50 mg/kg b.w., i.p., suspended in 1% Tween 80.

Group 3: glibenclamide at a dosage of 50 mg/kg b.w., i.p. 30 min before alpha-lipoic acid at a dosage of 50 mg/kg b.w., i.p.

Group 4: 0.25 mL of 1% Tween 80-control group.

All experiments were conducted according to the guidelines of the Animal Use and Care Committee of the Jagiellonian University (No.: 96/2011, date: 09.21.2011). The entire surgery was performed under thiopental anesthesia, and all efforts were made to minimize suffering.

The rats were anesthetized with thiopental (70 mg/kg) by an intraperitoneal injection. The left carotid artery was cannulated with a polyethylene tubing filled with heparin solution in saline to facilitate pressure measurements using the Datamax apparatus (Columbus Instruments, Ohio). Blood pressure was measured prior to the administration of the compounds (time 0 min-control pressure) and 80 min thereafter.

Statistical analysis {#sec2-1}
--------------------

The results of the blood pressure measurements are presented as the means±S.E.M., and statistical significance of the differences was evaluated using a two-way ANOVA, Bonferroni's multiple comparison test (four groups and ten factors). The differences were considered statistically significant when p\<0.05.

Results {#sec1-3}
=======

Alpha-lipoic acid intraperitoneally administered at a dosage of 50 mg/kg of b.w significantly lowered blood pressure 50 min after the administration to rats \[systolic F(10,278)=2.828, p=0.0023; diastolic F(10.268)=3.689, p=0.0001\]. All animals survived the experience. There were no complications with the surgery. Glibenclamide (50 mg/kg) intraperitoneally administered 30 min before alpha-lipoic acid inhibited its in all the time measuring points, there was no statistically significant difference between the pressure indicated between the glibenclamide-treated groups and the control group (p\>0.05). The results are shown in [Figure 1](#F1){ref-type="fig"}. [Table 1](#T1){ref-type="table"} shows the percentage of pressure drops in each group.

![a, b. The effect of alpha-lipoic acid, glibenclamide, and both compounds on blood pressure after a single administration\
The data represent systolic (a) and diastolic (b) blood pressure, means±S.E.M., after the administration of alpha-lipoic acid (50 mg/kg b.w., intraperitoneal injection)-LA group, or glibenclamide (50 mg/kg b.w., intraperitoneal injection)--G group, or alpha-lipoic acid (50 mg/kg b.w., intraperitoneal injection) plus glibenclamide (50 mg/kg b.w., intraperitoneal injection)-LA+G group, or 1% Tween 80 (0.25 mL, intraperitoneal injection)-control group; \*significant LA group vs. control group in each time point: \**P*\<0.05, \*\**P*\<0.01 (two-way ANOVA, Bonferroni's multiple comparison test)](AJC-16-306-g001){#F1}

###### 

The percentage of changes in systolic blood pressure

  Group\\time   5       10      15      20      30      40      50      60      70      80
  ------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  Control       -0.9    -2.19   -3.33   -4.31   -4.69   -6.58   -5.6    -6.73   -4.69   -6.58
  LA            -0.15   1.16    1.54    -2.86   -5.17   -8.88   -11.2   -18.2   -15.8   -17.8
  G             7.9     9.82    -0.24   1.58    1.35    -0.79   2.93    2.14    4.28    6.33
  LA+G          12.16   2.54    1.64    6.41    5.59    6.41    7.64    6.25    5.18    6.41

Groups: control-0.25 mL of 1% Tween 80; G-glibenclamide at a dose of 50 mg/kg b.w., i.p., suspended in 1% Tween 80; LA--alpha-lipoic acid at a dose of 50 mg/kg b.w., i.p., suspended in 1% Tween 80; LA+G - glibenclamide at a dose of 50 mg/kg b.w., i.p. 30 min before alpha-lipoic acid at a dose of 50 mg/kg b.w., i.p.; Time after administration \[min\]

Discussion {#sec1-4}
==========

In this study we demonstrated a significant effect of alpha-lipoic acid at a dosage of 50 mg/kg of b.w. on blood pressure in rats after one intraperitoneal administration. Glibenclamide, a K~ATP~ channel antagonist, attenuated this effect.

There are many papers in literature describing the impact of the chronic administration of alpha-lipoic acid on blood pressure pointing to its hypotensive effect after repeated administration or prevention of the development of hypertension ([@ref8]-[@ref12]). However, there is no described effect of alpha-lipoic acid on blood pressure after a single administration. In the present study, alpha-lipoic acid was intraperitoneally administered to rats at a dosage of 50 mg/kg of b.w. It was demonstrated that this dosage significantly reduced blood pressure, but the effect was visible beginning from the 50^th^ minute after the administration. Typically, the hypotensive effect after intraperitoneal treatment with a blood pressure-lowering compound is faster. There may be various reasons explaining why the hypotensive effect was not manifested until 50^th^ minute after the administration, including poor absorption of the compound after the intraperitoneal administration. Alpha-lipoic acid may be subject to changes or metabolized before its activity may be expressed or it may induce the formation of blood pressure reducing agents.

We also performed studies on the impact of the co-administration of glibenclamide, an ATP-dependent potassium channel inhibitor because it is known that the K~ATP~ channel opening is involved in the integrated vasodilator response to H~2~S *in vivo* in rats and that this effect is abrogated by the glibenclamide-induced blockade of the K~ATP~ channel ([@ref13]).

Other studies have shown that glibenclamide abolishes the decongestant action of alpha-lipoic acid, suggesting that ATP-dependent potassium channels are involved in this action ([@ref14], [@ref15]) and that this effect could be associated with the formation of H~2~S.

There are reports indicating that the anti-inflammatory effect of alpha-lipoic acid may be associated with increased sulfane sulfur levels and H~2~S release ([@ref16]). Additionally, other thiols such as L-cysteine or glutathione may be sulfane sulfur donors ([@ref17], [@ref18]) and may increase the levels of H~2~S ([@ref17]). It has been demonstrated that H~2~S is released from bound sulfur in the presence of physiological concentrations of glutathione and cysteine under slightly alkaline conditions. Extracellular potassium increases the intracellular pH to the level that supports H~2~S release ([@ref17]).

Therapy for cardiovascular system diseases utilizes the cardioprotective properties of compounds such as nicorandil (coronary heart disease), narcotic analgesics (post-myocardial infarction medication, cardioprotective effect), and adenosine (arrhythmias) for opening ATP-dependent potassium channels. Nicorandil opens K~ATP~ channels, thereby dilating peripheral resistance and coronary arterioles. It may cause a decrease in preload and blood pressure. Therefore, the results are very interesting, suggesting that alpha-lipoic acid, a drug used in diabetic neuropathy, may have cardioprotective properties related to this mechanism.

Study limitations {#sec1-5}
=================

The most important limitation of our study was the lack of detailed studies at the cellular level.

Another very important limitation of our study was the duration of the experiment.

Conclusion {#sec1-6}
==========

This study suggests that the observed effect of alpha-lipoic acid on blood pressure is associated with increased levels of sulfane sulfur, opening of ATP-dependent potassium channels, and release of H~2~S.

The results obtained in this study are very important because the patients taking alpha-lipoic acid may be treated for co-existing hypertension. Therefore, they must take into account the possibility of the blood pressure-lowering effect of alpha-lipoic acid that does not lead to excessive orthostatic hypotension.
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